Drug Trial Radar · NCT00369577
Staccato Loxapine in Agitation (Proof of Concept)
Last checked: Nov 20, 2026Latest source record: Jan 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Aug 2006
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- Alexza Pharmaceuticals, Inc.Not stated
- Sponsor type
- Not stated
- First posted
- Aug 29, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients. The study will be conducted in 120 agitated schizophrenic patients - either newly admitted to a hospital setting or a research unit for acute agitation or already in hospital for chronic underlying conditions. Patients meeting entry criteria will be randomized to one of two doses of Staccato Loxapine or to Staccato Placebo. Following administration of study drug, assessment of agitation state will be conducted at serial time points using standard agitation scales over a 24 hour period.
Conditions
- Schizophrenia
Interventions
Inhaled PlaceboDrug
Inhaled Placebo, single dose
Inhaled Loxapine 5 mgDrug
Inhaled Staccato Loxapine 5 mg, single dose
Inhaled Loxapine 10 mgDrug
Inhaled Staccato Loxapine 10 mg, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- PANSS-EC Change From BaselineTime frame: 2 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pacific Clinical Research Medical Group, 1317 West Foothill Blvd, Suite 200,
Upland, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.